Dr. Michelle Arkin is a chemical biologist, Professor and Chair of Pharmaceutical Chemistry, and Director of the Small Molecule Discovery Center (SMDC) at the University of California, San Francisco (UCSF). Dr. Arkin’s research focuses on developing methods and molecules that target currently ‘undruggable proteins,’ including protein-protein interactions and dynamic or intrinsically disordered proteins. The SMDC engages in collaborative drug discovery research, capitalizing on tools and expertise in high-throughput screening, fragment-based drug discovery, and medicinal chemistry. Dr. Arkin is an investigator in the UCSF Cancer Center, the Tau Consortium, and the Bakar Aging Research Institute, and is an Adjunct Professor at the Buck Institute for Research in Aging. She is involved with the academic drug discovery community, as Director and former President of the Academic Drug Discovery Consortium, Fellow and former Director of the Society for Laboratory Automation and Screening, and editor of the National Institutes of Health Assay Guidance Manual. Dr. Arkin is a cofounder and Director of Ambagon Therapeutics and cofounder of Elgia Therapeutics.